Medical devices, healthcare technology and the business of care
510(k) clearance · K261625

FAQ (FAQ 401);FAQ (FAQ 402)

Foreo, Inc. · Decision date Oct 26, 2026

FDA DECISIONK261625

What did the FDA decide?

FDA records K261625 as a 510(k) premarket notification, with a decision dated Oct 26, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
Oct 26, 2026

FDA source record

Regulatory record facts

Identifier
K261625
Regulatory pathway
510(k) premarket notification
Applicant
Foreo, Inc.
Product code
NFO
Decision code
SESE
Decision date
Oct 26, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, Transcutaneous Electrical, Aesthetic Purposes.

Applicant
Foreo, Inc.
Product code
NFO
FDA device class
2

FDA decision timeline

  1. K261625 received

    Application receipt date recorded by FDA.

  2. K261625 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code NFO

Product / regulatory recordCompanyPathwayDecision dateSource
Foreo, Inc.510(k) clearanceOct 22, 2026FDA
Guangdong Newdermo Biotech Co., Ltd.510(k) clearanceSep 16, 2026FDA
Xtreem Pulse, LLC510(k) clearanceSep 11, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Foreo, Inc.

Headquarters
Not reported
Brand website
foreo.com
FDA applicant address
Las Vegas, NV

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records